The December 31, 2026 DEA telehealth deadline adds urgency to a decision that should be carefully considered. Choosing a TRT platform isn't just about who has the best price today — it's about who will still be able to prescribe and deliver your medication in 2027 and beyond.
Vetting Criteria for 2026
1. Regulatory Preparedness
The most important differentiator between platforms right now:
- Ask: "What is your plan if the DEA telehealth flexibility expires without extension or Special Registration?"
- Good answers: "We're establishing clinical partnerships for in-person evaluations," "Our clinicians are preparing Special Registration applications," "We have contingency plans for both scenarios."
- Bad answers: "We don't expect any changes," silence, or deflection.
2. Clinical Quality Indicators
What to Evaluate
- Lab comprehensiveness: Does the platform check total T, free T, SHBG, estradiol, CBC, metabolic panel, PSA, and thyroid? Platforms that only check total testosterone are cutting clinical corners.
- Two-test diagnosis: Does the platform require two confirmed low testosterone values before prescribing? Single-test diagnosis is a quality red flag.
- Monitoring frequency: Labs at 6 weeks, then quarterly for the first year, then semiannually. Less frequent monitoring is substandard.
- Provider accessibility: Can you reach your prescriber with questions between scheduled visits? Messaging, phone, or telehealth on demand?
- Protocol flexibility: Will the platform adjust injection frequency, carrier oil, and adjunct medications based on your individual response — or is it one-size-fits-all?
3. Pharmacy Quality
- Which compounding pharmacy fills prescriptions? Is it PCAB-accredited?
- Is there a backup pharmacy if the primary has supply issues?
- Can you switch to a different carrier oil if needed?
4. Pricing Transparency
- All-inclusive monthly price vs. à la carte billing?
- Are labs, consultations, and adjunct medications included or separate?
- What's the cancellation policy and contract commitment?
The Bottom Line
Choose for 2027, Not Just 2026
The best TRT platform in 2026 is the one that will still be operating effectively in 2027 — regardless of what the DEA decides. Prioritize regulatory preparedness, clinical quality, pharmacy reliability, and pricing transparency. A platform that can't articulate a post-December-31 plan shouldn't get your subscription.